- Home
- JBGS vs VOR Comparison
JBGS vs VOR Comparison
Compare JBGS & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JBGS | VOR |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | 76 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 906.3M | 813.3M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | JBGS | VOR |
|---|---|---|
| Price | $14.79 | $14.99 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 1 | 10 |
| Target Price | $15.00 | ★ $45.33 |
| AVG Volume (30 Days) | 563.7K | ★ 800.4K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.69% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $498,598,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.99 | $0.18 |
| 52 Week High | $24.30 | $49.95 |
Technical Indicators
Market Signals| Indicator | JBGS | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 48.15 | 49.60 |
| Support Level | $14.13 | $13.73 |
| Resistance Level | $16.07 | $16.87 |
| Average True Range (ATR) | 0.38 | 0.98 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 46.75 | 26.56 |
Price Performance
Historical ComparisonAbout JBGS JBG SMITH Properties
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party real estate services. It generates maximum revenue from the commercial segment.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.